11ÔÂ28ÈÕ£¬£¬£¬£¬£¬£¬¹ú¼ÒÒ½ÁƱ£ÕϾ֡¢ÈËÁ¦×ÊÔ´ºÍÉç»á±£Õϲ¿Õýʽ·¢²¼ÁË¡¶¹ú¼Ò»ù±¾Ò½ÁƱ£ÏÕ¡¢¹¤É˱£ÏÕºÍÉúÓý±£ÏÕҩƷĿ¼(2024Äê)¡·¡£¡£¡£¡£¡£¡£¡£¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ¾­Ì¸ÅÐÊ״α»ÄÉÈë¹ú¼ÒÒ½±£Ä¿Â¼¡£¡£¡£¡£¡£¡£¡£¡£Ð°æĿ¼½«ÓÚ2025Äê1ÔÂ1ÈÕÕýʽʵʩ¡£¡£¡£¡£¡£¡£¡£¡£

ÊæËÙ´ï^®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ

       ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÊô±´ÌØÀàѪ֬µ÷½ÚÒ©£¬£¬£¬£¬£¬£¬Í¨¹ýÒÖÖƼ«µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥µÄÉú³É²¢Í¬Ê±Ê¹Æä·Ö½â´úлÔö¶à£¬£¬£¬£¬£¬£¬½µµÍѪµÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥£»£»£»£»£»£»£»£»»¹Ê¹ÔØÖ¬µ°°×A1ºÍA11Éú³ÉÔö¼Ó£¬£¬£¬£¬£¬£¬´Ó¶øÔö¸ß¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼¡£¡£¡£¡£¡£¡£¡£¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÓÅ»¯µ¨¼îÑνṹ£¬£¬£¬£¬£¬£¬¾ßÓнϺõÄË®ÈÜÐÔ£¬£¬£¬£¬£¬£¬ÏÔÖøÌáÉýÁËÉúÎïÀûÓöÈ^[1]£»£»£»£»£»£»£»£»Ò»´ÎÒ»Á££¨135mg£©,Ò»ÌìÒ»´Î£¬£¬£¬£¬£¬£¬ÎÞÐèÓë²Íͬ·þ£¬£¬£¬£¬£¬£¬ÌáÉýÓÃÒ©±ãÀûÐÔ^[2]¡£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£¿£¿£¿ÉÖ±½ÓÔÚÌåÄÚ·¢»Ó×÷ÓÃ£¬£¬£¬£¬£¬£¬ÎÞÐè¾­¹ý¸ÎÔàÊ×¹ý´úл£¬£¬£¬£¬£¬£¬´Ó¶ø¿É½µµÍ¸ÎÔฺµ£^[1]¡£¡£¡£¡£¡£¡£¡£¡£ËµÃ÷ÊéÖ¸³ö£¬£¬£¬£¬£¬£¬±¾Æ·ÓëËûÍ¡ÀàÒ©ÎïÁªºÏʹÓÃÎÞÐèµ÷Õû±¾Æ·»òºÏÓÃÒ©ÎïµÄ¼ÁÁ¿¡£¡£¡£¡£¡£¡£¡£¡£

ºÏ×÷×ÉѯÈÈÏß:4001833668

¿ÉɨÂëµÇ¼ÇºÏ×÷ÐÅÏ¢

²Î¿¼×ÊÁÏ£º

[1]     Elisavet Moutzouri ,Anastazia Kei,Moses S elisaf ,Haralampos J Milionis.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vascular Health and Risk Management 2010:6 525–539.

[2]   ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ˵Ã÷Êé.